Neomorph and Novo Nordisk Partner to Discover Molecular Glue Degraders for Cardiometabolic and Rare Diseases
Shots:
- Neomorph has signed a collaboration and licensing agreement with Novo Nordisk for the discovery, development and commercialization of molecular glue degraders
- Under the collaboration, Neomorph is entitled to receive an upfront payment, near-term milestones & R&D funding plus future clinical, commercial & sales milestones making it a total deal value of $1.46B along with tiered royalties
- Neomorph is responsible for lead discovery & preclinical studies of the selected candidates while Novo Nordisk gains exclusive rights for further clinical activities & commercialization of the compounds
Ref: PR Newswire | Image: Novo Nordisk
Related News:- Almirall Received EC’s Approval for Ebglyss (lebrikizumab) to Treat Moderate-to-severe Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
